Argus Research
- Home
- VIR
as of 12-08-2025 11:25am EST
$6.57
+$0.07
+1.00%
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Chart Type:
Time Range:
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 773.5M | IPO Year: | 2019 |
| Target Price: | $25.73 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.16 - $14.45 | Next Earning Date: | 11-05-2025 |
| Revenue: | $16,860,000 | Revenue Growth: | -78.56% |
| Revenue Growth (this year): | -91.46% | Revenue Growth (next year): | 48.05% |
AI-Powered VIR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 73.83%
73.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
SATO VICKI L
Sell
Director
VIR Dec 1, 2025
Avg Cost/Share
$6.00
Shares
22,000
Total Value
$132,070.40
Owned After
1,188,391
SEC Form 4
SVF Endurance (Cayman) Ltd
Sell
10% Owner
VIR Dec 1, 2025
Avg Cost/Share
$5.98
Shares
191,854
Total Value
$1,147,785.74
Owned After
13,728,924
SEC Form 4
SVF Endurance (Cayman) Ltd
Sell
10% Owner
VIR Nov 28, 2025
Avg Cost/Share
$6.44
Shares
61,493
Total Value
$396,014.92
Owned After
13,728,924
SEC Form 4
SVF Endurance (Cayman) Ltd
Sell
10% Owner
VIR Nov 26, 2025
Avg Cost/Share
$6.39
Shares
127,938
Total Value
$817,651.76
Owned After
13,728,924
SEC Form 4
SVF Endurance (Cayman) Ltd
Sell
10% Owner
VIR Nov 25, 2025
Avg Cost/Share
$6.38
Shares
235,971
Total Value
$1,505,494.98
Owned After
13,728,924
SEC Form 4
SVF Endurance (Cayman) Ltd
Sell
10% Owner
VIR Nov 24, 2025
Avg Cost/Share
$6.15
Shares
227,803
Total Value
$1,400,783.43
Owned After
13,728,924
SEC Form 4
O'Byrne Jason
Sell
EVP & Chief Financial Officer
VIR Nov 17, 2025
Avg Cost/Share
$5.56
Shares
6,799
Total Value
$37,782.04
Owned After
110,701
SEC Form 4
de Verneuil Vanina
Sell
EVP, General Counsel, Corp Sec
VIR Nov 5, 2025
Avg Cost/Share
$5.16
Shares
2,385
Total Value
$12,306.60
Owned After
78,210
SEC Form 4
SATO VICKI L
Sell
Director
VIR Nov 3, 2025
Avg Cost/Share
$5.64
Shares
22,000
Total Value
$124,047.00
Owned After
1,188,391
SEC Form 4
de Verneuil Vanina
Sell
EVP and General Counsel
VIR Nov 3, 2025
Avg Cost/Share
$5.86
Shares
1,365
Total Value
$8,003.00
Owned After
78,210
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| SATO VICKI L | VIR | Director | Dec 1, 2025 | Sell | $6.00 | 22,000 | $132,070.40 | 1,188,391 | |
| SVF Endurance (Cayman) Ltd | VIR | 10% Owner | Dec 1, 2025 | Sell | $5.98 | 191,854 | $1,147,785.74 | 13,728,924 | |
| SVF Endurance (Cayman) Ltd | VIR | 10% Owner | Nov 28, 2025 | Sell | $6.44 | 61,493 | $396,014.92 | 13,728,924 | |
| SVF Endurance (Cayman) Ltd | VIR | 10% Owner | Nov 26, 2025 | Sell | $6.39 | 127,938 | $817,651.76 | 13,728,924 | |
| SVF Endurance (Cayman) Ltd | VIR | 10% Owner | Nov 25, 2025 | Sell | $6.38 | 235,971 | $1,505,494.98 | 13,728,924 | |
| SVF Endurance (Cayman) Ltd | VIR | 10% Owner | Nov 24, 2025 | Sell | $6.15 | 227,803 | $1,400,783.43 | 13,728,924 | |
| O'Byrne Jason | VIR | EVP & Chief Financial Officer | Nov 17, 2025 | Sell | $5.56 | 6,799 | $37,782.04 | 110,701 | |
| de Verneuil Vanina | VIR | EVP, General Counsel, Corp Sec | Nov 5, 2025 | Sell | $5.16 | 2,385 | $12,306.60 | 78,210 | |
| SATO VICKI L | VIR | Director | Nov 3, 2025 | Sell | $5.64 | 22,000 | $124,047.00 | 1,188,391 | |
| de Verneuil Vanina | VIR | EVP and General Counsel | Nov 3, 2025 | Sell | $5.86 | 1,365 | $8,003.00 | 78,210 |
Latest Vir Biotechnology Inc. News
VIR Breaking Stock News: Dive into VIR Ticker-Specific Updates for Smart Investing
Compare VIR vs Leading Stocks
See how VIR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.